Key messages on obesity care from the 2023 ASPEN Physician Preconference Course: A narrative review.
anti‐obesity medications
bariatric surgery
malnutrition
obesity
sacropenic obesity
Journal
JPEN. Journal of parenteral and enteral nutrition
ISSN: 1941-2444
Titre abrégé: JPEN J Parenter Enteral Nutr
Pays: United States
ID NLM: 7804134
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
revised:
11
03
2024
received:
15
09
2023
accepted:
29
03
2024
medline:
12
5
2024
pubmed:
12
5
2024
entrez:
12
5
2024
Statut:
aheadofprint
Résumé
Obesity is a challenging chronic disease process that continues to affect a large percentage of the population at large. With the advent of new therapeutic options and interventions and a deeper scientific understanding of obesity as a complex illness, there is hope in curtailing this evolving pandemic. In this article, we present key medical information to engage and empower nutrition-focused providers to manage obesity and its nutrition complications. The topics summarized here were presented during the 2023 American Society for Parenteral and Enteral Nutrition Preconference Physician Course and include pathophysiology and hormonal regulation of obesity, multidisciplinary care planning and nutrition risk stratification of patients, and common approaches to treatment, including lifestyle modifications, antiobesity medications, and procedures from the perspective of the nutrition specialist.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition.
Références
Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960‐1994. Int J Obes Relat Metab Disord. 1998;22(1):39‐47.
Adult Obesty Prevalence Maps. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. 2023. Accessed April 19, 2024. https://www.cdc.gov/obesity/data/prevalence-maps.html
Gasmi A, Bjørklund G, Mujawdiya PK, et al. Micronutrients deficiences in patients after bariatric surgery. Eur J Nutr. 2022;61(1):55‐67.
Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49‐64.
Pi‐Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21‐33.
Popkin BM, Corvalan C, Grummer‐Strawn LM. Dynamics of the double burden of malnutrition and the changing nutrition reality. Lancet. 2020;395(10217):65‐74.
Barazzoni R, Gortan Cappellari G. Double burden of malnutrition in persons with obesity. Rev Endocr Metab Disord. 2020;21(3):307‐313.
Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321‐335.
Javed Z, Valero‐Elizondo J, Maqsood MH, et al. Social determinants of health and obesity: findings from a national study of US adults. Obesity. 2022;30(2):491‐502.
Barrientos‐Gutierrez T, Moore KAB, Auchincloss AH, et al. Neighborhood physical environment and changes in body mass index: results from the multi‐ethnic study of atherosclerosis. Am J Epidemiol. 2017;186(11):1237‐1245.
Cummins S, Macintyre S. Food environments and obesity—neighbourhood or nation? Int J Epidemiol. 2005;35(1):100‐104.
Braveman P, Paula, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129(2):19‐31.
Holt MK, Richards JE, Cook DR, et al. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP‐1, mediate stress‐induced hypophagia, and limit unusually large intakes of food. Diabetes. 2019;68(1):21‐33.
Krieger J‐P. Intestinal glucagon‐like peptide‐1 effects on food intake: physiological relevance and emerging mechanisms. Peptides. 2020;131:170342.
Holst JJ. Incretin hormones and the satiation signal. Int J Obes. 2013;37(9):1161‐1168.
Zaffina I, Pelle MC, Armentaro G, et al. Effect of dual glucose‐dependent insulinotropic peptide/glucagon‐like peptide‐1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol. 2023;14:1095753.
Fujita Y, Wideman RD, Asadi A, et al. Glucose‐dependent insulinotropic polypeptide is expressed in pancreatic islet α‐cells and promotes insulin secretion. Gastroenterology. 2010;138(5):1966‐1975.e1.
Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep for a healthy adult: a Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep. 2015;38(6):843‐844.
Papatriantafyllou E, Efthymiou D, Zoumbaneas E, Popescu CA, Vassilopoulou E. Sleep deprivation: effects on weight loss and weight loss maintenance. Nutrients. 2022;14(8):1549.
Taheri S, Lin L, Austin D, Young T, Mignot E. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med. 2004;1(3):e62.
Greer SM, Goldstein AN, Walker MP. The impact of sleep deprivation on food desire in the human brain. Nat Commun. 2013;4:2259.
Fenton S, Burrows TL, Collins CE, et al. Behavioural mediators of reduced energy intake in a physical activity, diet, and sleep behaviour weight loss intervention in adults. Appetite. 2021;165:105273.
Lee A, Cardel M, Donahoo WT. Social and environmental factors influencing obesity. In: Feingold KR, Anawalt B, Blackman MR, et al. eds. Endotext [Internet]. MDText.com, Inc; 2000. https://www.ncbi.nlm.nih.gov/books/NBK278977/
Dewi RC, Rimawati N, Purbodjati I. Body mass index, physical activity, and physical fitness of adolescence. J Public Health Res. 2021;10(2):2230.
Wilson K. Obesity: lifestyle modification and behavior interventions. FP Essent. 2020;492:19‐24.
Foster D, Sanchez‐Collins S, Cheskin LJ. Multidisciplinary team‐based obesity treatment in patients with diabetes: current practices and the state of the science. Diabetes Spectr. 2017;30(4):244‐249.
Fabricatore AN. Behavior therapy and cognitive‐behavioral therapy of obesity: is there a difference? J Am Diet Assoc. 2007;107(1):92‐99.
Yu B, Chen Y, Qin H, Chen Q, Wang J, Chen P. Using multi‐disciplinary teams to treat obese patients helps improve clinical efficacy: the general practitioner's perspective. Am J Transl Res. 2021;13(4):2571‐2580.
Curry SJ, Krist AH, Owens DK, et al. US Preventive Services Task Force. Behavioral weight loss interventions to prevent obesity‐related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163‐1171.
Van Baak MA, Mariman ECM. Obesity‐induced and weight‐loss‐induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023;19(11):655‐670.
Willett W, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6 suppl):1402S‐1406S.
Wadden TA, West DS, Delahanty L, et al. Look AHEAD Research Group The Look AHEAD Study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14(5):737‐752.
Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta‐analysis of randomized controlled trials. Adv Nutr. 2020;11(5):1150‐1160.
Gregg E, Jakicic J, Blackburn G, et al. Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long‐term cardiovascular disease outcomes in overweight or obese people with T2DM: a post‐hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabets Endocrinol. 2016;4(11):913‐921.
Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocrine Practice. 2016;22(suppl 3):1‐203.
Yumuk V, Tsigos C, Fried M, et al. Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402‐424.
Jabekk PT, Moe IA, Meen HD, Tomten SE, Høstmark AT. Resistance training in overweight women on a ketogenic diet conserved lean body mass while reducing body fat. Nutr Metab (Lond). 2010;7:17.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205‐216.
US Food and Drug Administration. Highlights of prescribing information: MOUNJARO. Accessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as an add‐on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56‐week, double‐blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341‐354.
Ghusn W, De la Rosa A, Sacoto D, et al. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5(9):e2231982.
US Food and Drug Administration. Highlights of prescribing information: OZEMPIC. Accessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
US Food and Drug Administration. Highlights of prescribing information: VICTOZA. Accsessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s027lbl.pdf
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687‐699.
US Food and Drug Administration. Highlights of prescribing information: QSYMIA. Accessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf
US Food and Drug Administration. Highlights of prescribing information: CONTRAVE. Accessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf
US Food and Drug Administration. Highlights of prescribing information: XENICAL. Accessed April 19, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf
Klein S, Romijn JA. Chapter 36: Obesity. In: Williams Textbook of Endocrinology. 13th ed. Elsevier; 2016:1633‐1659.
Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013;47(3):340‐349.
Apovian CM. Naltrexone/bupropion for the treatment of obesity and obesity with type 2 diabetes. Future Cardiol. 2016;12(2):129‐138.
Jain S, Ramanand S, Ramanand J, Akat P, Patwardhan M, Joshi S. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011;15(2):99‐104.
Al Suwaidi J. STAMPEDE: bariatric surgery gains more evidence based support. Glob Cardiol Sci Pract. 2014;2014(1):8.
Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043‐1053.e4.
Sepúlveda M, Alamo M, Saba J, Astorga C, Lynch R, Guzmán H. Long‐term weight loss in laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2017;13(10):1676‐1681.
Corcelles R, Boules M, Froylich D, et al. Total weight loss as the outcome measure of choice after Roux‐en‐Y gastric bypass. Obes Surg. 2016;26(8):1794‐1798.
Jiménez A, Ibarzabal A, Moizé V, et al. Ten‐year outcomes after Roux‐en‐Y gastric bypass and sleeve gastrectomy: an observational nonrandomized cohort study. Surg Obes Relat Dis. 2019;15(3):382‐388.
Sethi M, Chau E, Youn A, Jiang Y, Fielding G, Ren‐Fielding C. Long‐term outcomes after biliopancreatic diversion with and without duodenal switch: 2‐, 5‐, and 10‐year data. Surg Obes Relat Dis. 2016;12(9):1697‐1705.
Gastrointestinal surgery for severe obesity. Consens Statement. 1991;9(1):1‐20.
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345‐1356.
American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011‐2020. 2022.
Public Education Committee. Bariatric surgery procedures. 2021. Accessed April 19, 2024. https://asmbs.org/patients/bariatric-surgery-procedures
Chierici A, Chevalier N, Iannelli A. Postoperative morbidity and weight loss after revisional bariatric surgery for primary failed restrictive procedure: a systematic review and network meta‐analysis. Int J Surg. 2022;102:106677.
Di Lorenzo N, Antoniou SA, Batterham RL, et al. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO‐EC, EASO and ESPCOP. Surg Endosc. 2020;34(6):2332‐2358.
Marceau P, Biron S, Marceau S, et al. Long‐term metabolic outcomes 5 to 20 years after biliopancreatic diversion. Obes Surg. 2015;25:1584‐1593.
Verhoeff K, Mocanu V, Jogiat U, et al. Patient selection and 30‐day outcomes of SADI‐S compared to RYGB: a retrospective cohort study of 47,375 patients. Obes Surg. 2022;32(7):1‐8.
Felsenreich DM, Steinlechner K, Langer FB, et al. Outcome of sleeve gastrectomy converted to Roux‐en‐Y gastric bypass and one‐anastomosis gastric bypass. Obes Surg. 2022;32(3):643‐651.
Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures ‐ 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists ‐ executive summary. Endocr Pract. 2019;25(12):1346‐1359.
Kaouk L, Hsu AT, Tanuseputro P, Jessri M. Modifiable factors associated with weight regain after bariatric surgery: a scoping review. F1000Research. 2019;8:615.